Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.
2.

Antibody-mediated rejection and treatment in pediatric patients: one center's experience.

Gulleroglu K, Baskin E, Bayrakci US, Turan M, Ozdemir BH, Moray G, Karakayali H, Haberal M.

Exp Clin Transplant. 2013 Oct;11(5):404-7.

3.

Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.

Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J.

J Heart Lung Transplant. 2011 Dec;30(12):1320-6. doi: 10.1016/j.healun.2011.08.009.

PMID:
21968130
4.

Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.

Asante-Korang A, Jacobs JP, Ringewald J, Carapellucci J, Rosenberg K, McKenna D, McCormack J, Wilmot I, Gjeldum A, Lopez-Cepero M, Sleasman J.

Cardiol Young. 2011 Dec;21 Suppl 2:124-32. doi: 10.1017/S1047951111001703. Review.

PMID:
22152539
5.

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation.

Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, Silver MA, Radvany R, Robinson JA.

J Heart Lung Transplant. 1999 Jul;18(7):701-6.

PMID:
10452347
6.

Treatment of acute antibody-mediated rejection: a single-center experience.

Rodríguez Ferrero M, Rincón A, Bucalo L, Rementería A, Anaya F.

Transplant Proc. 2010 Oct;42(8):2848-50. doi: 10.1016/j.transproceed.2010.07.068.

PMID:
20970547
7.

Acute antibody-mediated rejection in paediatric renal transplant recipients.

Kranz B, Kelsch R, Kuwertz-Bröking E, Bröcker V, Wolters HH, Konrad M.

Pediatr Nephrol. 2011 Jul;26(7):1149-56. doi: 10.1007/s00467-011-1864-3.

PMID:
21461632
8.

The Impella 2.5 L for percutaneous mechanical circulatory support in severe humoral allograft rejection.

Beyer AT, Hui PY, Hauesslein E.

J Invasive Cardiol. 2010 Mar;22(3):E37-9.

PMID:
20197587
9.

Antibody-mediated rejection in heart transplant patients: long-term follow up of patients with high levels of donor-directed anti-DQ antibodies.

Ticehurst EH, Molina MR, Frank R, Kearns J, Lal P, Goldberg LR, Tsai D, Wald J, Kamoun M.

Clin Transpl. 2011:409-14.

PMID:
22755439
10.

Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection.

Loyaga-Rendon RY, Taylor DO, Koval CE.

Am J Transplant. 2013 Apr;13(4):1075-9. doi: 10.1111/ajt.12153.

11.

Relationship between bridging with ventricular assist device on rejection after heart transplantation.

Pamboukian SV, Costanzo MR, Dunlap S, Rayburn B, Westfall AO, You ZY, Hung E, McLeod M, Heroux A.

J Heart Lung Transplant. 2005 Mar;24(3):310-5.

PMID:
15737758
12.

Humoral rejection after pediatric heart transplantation: a case report.

Stendahl G, Berger S, Ellis T, Gandy K, Mitchell M, Tweddell J, Zangwill S.

Prog Transplant. 2010 Sep;20(3):288-91.

PMID:
20929115
13.

Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.

Ibernón M, Gil-Vernet S, Carrera M, Serón D, Moreso F, Bestard O, Cruzado JM, Grinyó JM.

Transplant Proc. 2005 Nov;37(9):3743-5.

PMID:
16386524
14.

Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.

Drakos SG, Kfoury AG, Long JW, Stringham JC, Fuller TC, Nelson KE, Campbell BK, Gilbert EM, Renlund DG.

Ann Thorac Surg. 2006 Sep;82(3):889-93.

PMID:
16928502
15.

Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.

Jin MK, Cho JH, Kwon O, Hong KD, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.

Transplant Proc. 2012 Jan;44(1):200-3. doi: 10.1016/j.transproceed.2011.11.040.

PMID:
22310614
16.

Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.

Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, Jeon HJ, Han M, Ahn C, Yang J.

Nephrology (Carlton). 2013 Dec;18(12):820-6. doi: 10.1111/nep.12157.

PMID:
24033843
17.

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

Waiser J, Budde K, Schütz M, Liefeldt L, Rudolph B, Schönemann C, Neumayer HH, Lachmann N.

Nephrol Dial Transplant. 2012 Mar;27(3):1246-51. doi: 10.1093/ndt/gfr465.

18.

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.

Koch M, Gräser C, Lehnhardt A, Pollok JM, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B.

Transpl Int. 2013 Aug;26(8):e64-8. doi: 10.1111/tri.12120.

19.

A survey of current practice for antibody-mediated rejection in heart transplantation.

Chih S, Tinckam KJ, Ross HJ.

Am J Transplant. 2013 Apr;13(4):1069-74. doi: 10.1111/ajt.12162.

20.

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE.

Transplantation. 2000 Sep 27;70(6):887-95.

PMID:
11014642
Items per page

Supplemental Content

Support Center